Myriad Partners with Sanofi, Biogen Makes 3rd Deal with Isis: Healthcare Business Report

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

In a Monday press release, Myriad Genetics (NASDAQ:MYGN) said that its wholly owned subsidiary Myriad RBM, will partner with  Sanofi-Aventis (NYSE:SNY), a worldwide and diversified healthcare leader, and Population Health Research Institute at Hamilton Health Sciences and McMaster University. Through this partnership Myriad RBM will conduct protein biomarker research for the Outcome Reduction with Initial Glargine Intervention study, the world’s longest and largest randomized clinical trial in pre- and early diabetes.

Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.

Biogen IDEC (NASDAQ:BIIB), apparently quite impressed with the tech at Isis Pharmaceuticals (NASDAQ:ISIS), has made a third deal with the latter in very short order, paying $30 million upfront and pledging as much as $200 million more in milestones for each of three new programs targeted at neurological diseases and neuromuscular disorders. In all, Biogen has now paid Isis $71 million in upfront payments and and is committed to in excess of $1.1 billion in potential milestones.

Don’t Miss: Will “Pay for Delay” Ruling Cost Drug Companies?

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business